- Home
- CEV vs CRDL Comparison
CEV vs CRDL Comparison
Compare CEV & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEV
- CRDL
- Stock Information
- Founded
- CEV 1999
- CRDL 2017
- Country
- CEV United States
- CRDL Canada
- Employees
- CEV N/A
- CRDL N/A
- Industry
- CEV Finance/Investors Services
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CEV Finance
- CRDL Health Care
- Exchange
- CEV Nasdaq
- CRDL Nasdaq
- Market Cap
- CEV 67.8M
- CRDL 80.1M
- IPO Year
- CEV N/A
- CRDL N/A
- Fundamental
- Price
- CEV $9.62
- CRDL $1.25
- Analyst Decision
- CEV
- CRDL Strong Buy
- Analyst Count
- CEV 0
- CRDL 3
- Target Price
- CEV N/A
- CRDL $9.00
- AVG Volume (30 Days)
- CEV 19.6K
- CRDL 156.5K
- Earning Date
- CEV 01-01-0001
- CRDL 05-14-2025
- Dividend Yield
- CEV 4.23%
- CRDL N/A
- EPS Growth
- CEV N/A
- CRDL N/A
- EPS
- CEV 0.36
- CRDL N/A
- Revenue
- CEV N/A
- CRDL N/A
- Revenue This Year
- CEV N/A
- CRDL N/A
- Revenue Next Year
- CEV N/A
- CRDL N/A
- P/E Ratio
- CEV $29.36
- CRDL N/A
- Revenue Growth
- CEV N/A
- CRDL N/A
- 52 Week Low
- CEV $8.83
- CRDL $0.77
- 52 Week High
- CEV $10.91
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- CEV 42.26
- CRDL 63.31
- Support Level
- CEV $9.56
- CRDL $1.04
- Resistance Level
- CEV $9.82
- CRDL $1.31
- Average True Range (ATR)
- CEV 0.08
- CRDL 0.07
- MACD
- CEV -0.01
- CRDL 0.01
- Stochastic Oscillator
- CEV 32.35
- CRDL 77.94
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.